Zivo Bioscience, Inc. (ZIVO)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2024, Zivo Bioscience, Inc. reported revenue of $157.2K, up 468.6% from the prior year. The company ran a net loss, with a net margin of -8513.4% and a gross margin of 31.1%. It held $1.64M in total assets against $2.16M in total liabilities.
Key ratios (FY2024)
31.1%
Gross margin
-8498.9%
Operating margin
-8513.4%
Net margin
+468.6%
Revenue growth (YoY)
| Metric (FY) | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $157.2K | $27.6K | $0 | $0 | $20.0K | $0 | $0 | — | $0 | $0 |
| Cost of Revenue | $108.3K | $16.0K | $0 | — | — | — | — | — | — | — |
| Gross Profit | $49.0K | $11.6K | $0 | — | — | — | — | — | — | — |
| Operating Income | -$13.36M | -$7.26M | -$8.73M | -$8.65M | -$8.56M | -$8.35M | -$6.13M | -$6.33M | -$3.49M | -$3.06M |
| Net Income | -$13.38M | -$7.78M | -$8.75M | -$8.76M | -$9.11M | -$11.51M | -$14.64M | -$10.04M | -$6.06M | -$5.79M |
| EPS (Diluted) | $-4.23 | $-4.60 | — | — | — | — | — | — | — | — |
| Total Assets | $1.64M | $555.7K | $2.12M | $8.99M | $220.2K | $369.4K | $411.5K | $332.3K | $737.3K | $72.7K |
| Total Liabilities | $2.16M | $2.76M | $2.13M | $2.95M | $11.53M | $8.71M | $22.69M | $16.64M | $14.36M | $9.57M |
| Shareholders' Equity | -$514.9K | -$2.21M | -$10.6K | $6.04M | -$11.31M | -$8.34M | -$22.28M | -$16.30M | -$13.62M | -$9.50M |
| Cash & Equivalents | — | — | $1.80M | $8.90M | $137.9K | $346.1K | $388.9K | $317.1K | $507.0K | $16.6K |
| Operating Cash Flow | -$4.31M | -$5.80M | -$7.10M | -$6.80M | -$2.59M | -$3.71M | -$5.01M | -$4.24M | -$2.54M | -$2.30M |
| Shares Outstanding | 3.62M | 2.38M | 1.57M | 9.42M | 5.16M | 413.04M | 180.04M | 141.11M | 136.75M | 132.16M |
| Dividends Per Share | — | $3.11 | — | — | — | — | — | — | — | — |